{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"54.6","value":"65.3"},{"groupId":"OG001","spread":"19.3","value":"32.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"7"}],"units":"Participants"}],"title":"Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"59.9","value":"68.8"},{"groupId":"OG001","spread":"42.0","value":"34.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"title":"Day 15"}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"7"}],"units":"Participants"}],"dispersionType":"Standard Deviation","groups":[{"description":"Ixazomib 4.0 mg, capsules, orally, once, on Days 1, 8, and 15 in 28-day treatment cycle for up to Cycle 87.","id":"OG000","title":"Cohort 1: Ixazomib 4.0 mg"},{"description":"Ixazomib 4.0 mg, capsules, orally, once, on Days 1, 8, and 15 in 28-day treatment cycle along with lenalidomide 25 mg/day, capsules, orally, once, from Days 1 to 21 and dexamethasone 40 mg/day, tablets, orally, once, on Days 1, 8, 15, and 22 in a 28-day treatment cycle for up to Cycle 62.","id":"OG001","title":"Cohort 2: Ixazomib 4.0 mg + Lenalidomide and Dexamethasone"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"The pharmacokinetic (PK) analysis set consisted of all participants who received at least one dose of ixazomib and has evaluable PK data. The PK analysis set where data at specified time points was available.","reportingStatus":"POSTED","timeFrame":"Days 1 and 15 of Cycle 1: pre-dose and at multiple time points (15, 30, 60, and 90 minutes and 2, 4, 8, 24, 48, 96, and 168 hours) post-dose (Cycle length=28 days)","title":"Cmax: Maximum Observed Plasma Concentration for Ixazomib","type":"PRIMARY","unitOfMeasure":"nanogram per milliliter (ng/mL)"}